At Microbio, we’re proud to announce our latest step in global expansion – the signing of an exclusive distribution agreement with ELTA 90 MGR, a prominent distributor of advanced medical and laboratory diagnostics, to bring Microbio’s cutting-edge products to the Greek healthcare market.
This strategic partnership is a key milestone in Microbio’s global expansion plan and will help improve healthcare outcomes in Greece by providing access to its innovative diagnostic solutions. Microbio’s diagnostics, known for their accuracy, speed, and reliability, will now be available to healthcare providers across Greece through ELTA 90 MGR’s well-established distribution network.
InfectID™-BSI: A game-changer in sepsis diagnostics
At the forefront of our product lineup is InfectID™-BSI, an innovative molecular diagnostic test designed to identify 26 sepsis-causing pathogens directly from blood samples. This powerful test uses melt curve technology to detect the pathogen’s DNA ‘fingerprint’, delivering results in less than three hours—without the need for culture or enrichment.
Sepsis is a life-threatening condition, and early diagnosis is critical in saving lives. InfectID™-BSI provides healthcare providers with a fast, accurate tool to make timely treatment decisions, ultimately improving patient outcomes. As a CE-marked product, InfectID™-BSI is set to play a vital role in the fight against sepsis, and we are proud to introduce it to the Greek market.
About the partnership
This partnership is a testament to the shared vision and commitment of both Microbio and ELTA 90 MGR. With their deep expertise and established presence in the medical diagnostics field, ELTA 90 MGR is the ideal partner to help us bring our cutting-edge technology to healthcare providers across Greece.
Johan Vanderhoeven, Chief Commercial Officer at Microbio, expressed his excitement about the collaboration:
We are thrilled to collaborate with ELTA 90 MGR, a trusted and well-regarded distributor in Greece. Their expertise and reach in the medical diagnostics field make them the perfect partner to introduce our InfectID™-BSI test to the Greek healthcare system. Together, we aim to make a meaningful difference in the early detection and treatment of sepsis, saving lives and improving patient care.
Vasilis Koutsokostas, General Manager at ELTA 90 MGR, shared a similar sentiment:
On behalf of ELTA 90 MGR I am thrilled to announce the beginning of a new cooperation with Microbio that promises to bring exciting opportunities and innovative possibilities. Knowing very well the impact that sepsis has on millions of humans, we would be more than happy to play a small role in the fight against it. This collaboration merges our strengths and visions, paving the way for creative solutions and impactful results. I am eager to work alongside such talented individuals and explore the potential that this partnership holds. Together we hope to save human lives in Greece.
Looking ahead
This partnership marks an exciting chapter for Microbio as we continue to expand our presence in Europe and beyond. By working together with trusted partners like ELTA 90 MGR, we are one step closer to ensuring that life-saving diagnostics like InfectID™-BSI are accessible to healthcare providers worldwide.
For more information about the partnership and our products, visit microbio.com.au or elta90mgr.gr.